Does Rallies show Form 4 insider transactions for EVMN?

Yes. Rallies tracks EVMN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is EVMN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for EVMN. It does not provide personalized investment advice.

EVMN (Evommune, Inc.) Stock Analysis - Insider Trades

Evommune, Inc. (EVMN) is a publicly traded the market company. As of May 21, 2026, EVMN trades at $22.23 with a market cap of $788.44M and a P/E ratio of -1.95. EVMN moved +4.69% today. Year to date, EVMN is +44.96%; over the trailing twelve months it is flat. Its 52-week range spans $13.89 to $33.20. Analyst consensus is strong buy with an average price target of $52.00. Rallies surfaces EVMN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading EVMN stock inside the company?

Recent EVMN insider activity includes Hopfner Robert Lorne bought 1.00K, RA CAPITAL MANAGEMENT, L.P. bought 1.16M, RA CAPITAL MANAGEMENT, L.P. bought 92.90K, LSP 7 Cooperative UA bought 1.56M, and Verduyn-van Weegen Felice Isabel bought 1.56M. Rallies tracks insider transaction dates, shares, prices, and estimated values.

EVMN Key Metrics

Key financial metrics for EVMN
Metric	Value
Price	$22.23
Market Cap	$788.44M
P/E Ratio	-1.95
EPS	$-11.22
Dividend Yield	0.00%
52-Week High	$33.20
52-Week Low	$13.89
Volume	63
Avg Volume	0
Revenue (TTM)	$13.00M
Net Income	$-68.87M
Gross Margin	0.00%

Recent EVMN Insider Trades

Hopfner Robert Lorne bought 1.00K (~$17.35K) on Dec 19, 2025.
RA CAPITAL MANAGEMENT, L.P. bought 1.16M (~$18.51M) on Nov 7, 2025.
RA CAPITAL MANAGEMENT, L.P. bought 92.90K (~$1.49M) on Nov 7, 2025.
LSP 7 Cooperative UA bought 1.56M (~$25.00M) on Nov 7, 2025.
Verduyn-van Weegen Felice Isabel bought 1.56M (~$25.00M) on Nov 7, 2025.

Latest EVMN News

Evommune's Phase 2a Success Drives $65 Price Target and $125M Funding — Feb 15, 2026
Evommune Shares Slip After 70% Rally Following 33% Eczema Trial Gain — Feb 12, 2026

EVMN Analyst Consensus

8 analysts cover EVMN: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $52.00.

Common questions about EVMN

Who is trading EVMN stock inside the company?: Recent EVMN insider activity includes Hopfner Robert Lorne bought 1.00K, RA CAPITAL MANAGEMENT, L.P. bought 1.16M, RA CAPITAL MANAGEMENT, L.P. bought 92.90K, LSP 7 Cooperative UA bought 1.56M, and Verduyn-van Weegen Felice Isabel bought 1.56M. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for EVMN?: Yes. Rallies tracks EVMN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is EVMN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for EVMN. It does not provide personalized investment advice.